Caracterização da trajetória de desenvolvimento da indústria farmacêutica na Índia: elementos para aprendizado

Radaelli, Vanderleia; Paranhos, Julia
June 2013
Parcerias Estratégicas;jun2013, Vol. 18 Issue 36, p9
Academic Journal
Lately, certain developing countries have managed to gain important market shares in the pharmaceutical industry. While in many of these the strategies, governance and regulatory system for innovation are still being consolidated, this group of countries nevertheless has attracted the interest of large multinational companies. In this respect, India proves an emblematic case, showing the increased relevance of a developing country, traditionally dependent on the transfer of technologies, products and processes developed abroad, through building skills in an industry such as pharmaceuticals. The Indian pharmaceutical industry, at a 120 years, is relatively new. The changes occurred in India in the last 40 years have ignited a debate about the ability of a relatively poor country, with companies still in their structuring phase, to understand, assimilate and implement production processes for products that were previously generated abroad. This capacity, rather unusual, often portrayed in its early stages, during which the regime of intellectual property rights was not followed in the following terms: imitation versus innovation. Accordingly, the proper understanding of the evolution of the Indian pharmaceutical industry wants all the credit for changes in the regulatory regime as a key part of the current performance of their businesses in the international market, which is the goal of this article.


Related Articles

  • Patently pending. James, David // BRW;9/5/2002, Vol. 24 Issue 35, p64 

    Discusses the threat posed to intellectual property rights of developing countries by global corporations. Percentage of intellectual property rights held by the developed world; Problems in establishing an intellectual property regime; Need for effective intellectual property initiatives.

  • Foreign actors and intellectual property protection regulations in developing countries. Brandl, Kristin; Darendeli, Izzet; Mudambi, Ram // Journal of International Business Studies;Jul2019, Vol. 50 Issue 5, p826 

    International agreements and institutions affect innovation in developing countries. We analyze the impact of advanced country multinational enterprises (AMNEs) and supranational organizations on the regulatory adoption of global intellectual property protection standards. In particular, we...

  • The production of generic drugs in India: Would be affected by new trade agreement with EU. Love, James // BMJ: British Medical Journal (International Edition);4/2/2011, Vol. 342 Issue 7800, p721 

    The author reflects on the trade agreement negotiated between European Union (EU) and India which may affect the production of generic drugs. The author says that the deal, which restricts ownership and enforcement of intellectual property for medical inventions, if implemented, may shrink the...

  • The Ethics of Intellectual Property Rights in an Era of Globalization. Shah, Aakash Kaushik; Warsh, Jonathan; Kesselheim, Aaron S. // Journal of Law, Medicine & Ethics;Winter2013, Vol. 41 Issue 4, p841 

    Since the 1980s, developed countries, led by the United States and the countries of the European Union, have sought to incorporate intellectual property rights provisions into global trade agreements. These countries successfully negotiated the World Trade Organization's 1994 Agreement on...

  • Intellectual property, pharmaceutical MNEs and the developing world. Ghauri, Pervez N.; Rao, P.M. // Journal of World Business;Apr2009, Vol. 44 Issue 2, p206 

    Abstract: The paper examines the structure of pharmaceutical R&D funding, spillovers and public�private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives...

  • Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591 

    The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications...

  • Caution needed for Russian Expansion.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p10 

    The article indicates that accounting and consulting firm PricewaterhouseCoopers has released a report on the opportunities and problems associated with the pharmaceutical industry in Russia. It was observed that the legal system is much weaker than in the European Union, U.S. or Japan, and that...

  • ROLE OF INTELLECTUAL PROERTY RIGHTS (IPR) IN INDIAN AGRICULTURE-A BANE OR BOON. Mohanty, Smrutirekha; Das, Giridhari Prasad // VIDHIGYA: The Journal of Legal Awareness;Jul-Dec2013, p1 

    The progressive commercialization of agriculture in the developed countries has been linked to agriculture as an economic activity and as a provider of employment in the developing countries like India. Technological know-how is increasingly becoming a key determinant of market share in modern...

  • Drug patent plan gets mixed reviews. Butler, Declan // Nature;2/26/2009, Vol. 457 Issue 7233, p1 

    The article discusses the reaction to U.S. pharmaceutical company GlaxoSmithKline's (GSK) decision to share some of its patents to increase research efforts into neglected diseases and make its drugs available to the poorest countries through cheaper prices. Topics include an explanation of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics